Pharma's late-stage deal trend exposes new risks
This article was originally published in Scrip
Executive Summary
Pharma and biotech firms are exposing themselves to a potentially greater financial risk as they increasingly pursue late rather than early-stage compounds to balance the loss of more than $74 billion in sales by 2012, argues a new report by Deloitte.